Steris Q1 adjusted EPS beats estimates, revenue up 7%
Steris Q1 adjusted EPS beats estimates, revenue up 7%
Overview
Ireland-based infection prevention firm's fiscal Q1 revenue rose 7% yr/yr
Adjusted EPS for fiscal Q1 beat analyst expectations
Company announced restructuring plan tied to new chemistries Center of Excellence in North Carolina
Outlook
Steris reiterates fiscal 2027 revenue growth guidance of 7-8% as reported
Company expects fiscal 2027 adjusted EPS of $11.10 to $11.30
Steris raises fiscal 2027 capital expenditures outlook to $450 mln, lowers free cash flow view to $800 mln
Result Drivers
HEALTHCARE SEGMENT GROWTH - Co said Healthcare segment growth was driven by share gains in consumables and services, with solid order growth for capital equipment
PRICE AND VOLUME IMPROVEMENTS - Co attributed higher operating income in Healthcare and Life Sciences to improved volume, price, productivity and favorable mix, partially offset by inflation and tariff costs
AST SEGMENT MIXED RESULTS - Co said Applied Sterilization Technologies revenue rose on service growth but was held back by a decline in capital equipment sales
Company press release: ID:nGNX8CWFhT
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Adjusted EPS | Beat | $2.59 | $2.50 (7 Analysts) |
Q1 EPS |
| $2.04 |
|
Q1 Adjusted Net Income | Beat | $253.40 mln | $245.68 mln (5 Analysts) |
Q1 Net Income |
| $200.10 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for STERIS plc is $270.00, about 16% above its August 4 closing price of $232.85
The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 20 three months ago
Reuters Recommended Reads
Aug 5 - Steris to invest $600 million in new North Carolina chemicals manufacturing hub
Aug 5 - Solventum Q2 sales, adjusted EPS beat estimates; FY outlook lifted
Aug 4 - Revvity Q2 revenue beats estimates on diagnostics growth
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)